OncoDecipher

Tamir Tuller

Prof. Tuller holds an appointment of a full professor with tenure at Tel Aviv University where he is the head of the Laboratory of Computational Systems and Synthetic Biology. A central research interest of Prof. Tuller and his lab is developing computational approaches for modeling and engineering gene expression for various biotechnological/medical objectives.

​

Prof. Tuller has formal education and training in electrical engineering, mechanical engineering, computer science, medicine, and biology (four BSc, two MSc studies and two PhD titles). Before joining Tel-Aviv University he was a Koshland fellow at Weizmann Institute of Science in the faculty of mathematics and the faculty of molecular genetics.

​

Prof. Tuller is the author of more than 150 peer reviewed scientific journal articles in top journals and more than 200 other types of publications (conference papers, abstracts, book chapters, and patents). Prof. Tuller has received various awards and fellowships and he has vast experience as a collaborator with Israeli and international biotech companies.

OncoDecipher | Tamir Tuller

Decoding the hidden causes of cancer

Precision oncology relies on identifying genetic changes that drive cancer and can serve as targets for treatment. However, many disease-associated genetic variants do not directly alter the protein sequence, making their biological effects difficult to identify. As a result, many patients may not qualify for existing biomarker-driven treatments even when relevant genetic changes are present.

Developed from research led by Prof. Tamir Tuller, OncoDecipher uses artificial intelligence, computational biology, and molecular validation to uncover these previously hidden genetic biomarkers. The platform analyzes clinical and genetic patient data with state-of-the-art computational and bioinformatic tools, identifies novel variants, predicts their biological and therapeutic effects, and validates promising candidates. By expanding the range of genetic changes that can be recognized as cancer biomarkers, OncoDecipher aims to open new possibilities for personalized treatment and extend precision oncology to patients who currently have limited treatment options.

 

 

View More